FindTrial
Sign In

Establishing blood levels in normal individuals of markers that are dysregulated in cancerous tumours

Study to examine the baseline profile of exosomes in overtly healthy individuals

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2022/04/041837
Enrollment
50
Registered
2022-04-13
Start date
Unknown
Completion date
Unknown
Last updated
2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Exsegen Genomics Research Pvt Ltd
Lead Sponsor
Exsegen Genomics Research Pvt Ltd
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: -Male or female age of = 18 years and less than 80 at the time of signing informed consent form. -Provision of signed and dated informed consent form. -Fit and healthy individual.

Exclusion criteria

Exclusion criteria: -Patient in any active disease state Pregnancy -Patients suspected or diagnosed with any type of malignancy -Prolonged cortico-steroid therapy or immunosuppressive therapy -Active or latent hepatitis B or active hepatitis C or any uncontrolled infection at screening Human Immunodeficiency Virus (HIV) positive Active infections, COVID 19, HPV, HBV, HCV, Tuberculosis etc. -Patient has an investigational medicinal product within the last 30 days of blood collection.

Design outcomes

Primary

MeasureTime frame
The primary objective of this study is to examine the baseline exosomal profiles in healthy individuals.Timepoint: At baseline—

Secondary

MeasureTime frame
NilTimepoint: Nil—

Countries

India

Contacts

Public ContactDr Amitava Ray MBBS MD FRCSEd FRCS Neurosurgery

Senior Consultant Neurosurgeon

amit@exsegen.com9000420030

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026